UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Targeting multiple angiogenic pathways for the treatment of neuroblastoma
  • Publication Type:
    Journal article
  • Publication Sub Type:
    JOUR
  • Authors:
    Williams RF, Myers AL, Sims TL, Ng CY, Nathwani AC, Davidoff AM
  • Publication date:
    06/2010
  • Pagination:
    1103, 1109
  • Journal:
    J.Pediatr.Surg.
  • Volume:
    45
  • Issue:
    6
  • Keywords:
    Actins, administration & dosage, Animals, Antibiotics,Antineoplastic, Antigens,CD34, blood supply, Cluster Analysis, drug therapy, Humans, Immunohistochemistry, Immunologic Factors, Injections,Intraperitoneal, Interferon-beta, Male, metabolism, methods, Mice, Mice,Scid, Neoplasms,Experimental, Neovascularization,Pathologic, Neuroblastoma, pathology, Pericytes, Retroperitoneal Neoplasms, Sirolimus, therapeutic use, therapy, Transplantation,Heterologous, Tumor Cells,Cultured
  • Author URL:
  • Notes:
    DA - 20100712 IS - 1531-5037 (Electronic) IS - 0022-3468 (Linking) LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S RN - 0 (Actins) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Antigens, CD34) RN - 0 (Immunologic Factors) RN - 53123-88-9 (Sirolimus) RN - 77238-31-4 (Interferon-beta) SB - IM
Abstract
PURPOSE: Resistance to angiogenesis inhibition can occur through the upregulation of alternative mediators of neovascularization. We used a combination of angiogenesis inhibitors with different mechanisms of action, interferon-beta (IFN-beta) and rapamycin, to target multiple angiogenic pathways to treat neuroblastoma xenografts. METHODS: Subcutaneous and retroperitoneal neuroblastoma xenografts (NB-1691 and SK-N-AS) were used. Continuous delivery of IFN-beta was achieved with adeno-associated virus vector-mediated, liver-targeted gene transfer. Rapamycin was delivered intraperitoneally (5 mg/kg per day). After 2 weeks of treatment, tumor size was measured, and tumor vasculature was evaluated with intravital microscopy and immunohistochemistry. RESULTS: Rapamycin and IFN-beta, alone and in combination, had little effect on tumor cell viability in vitro. In vivo, combination therapy led to fewer intratumoral vessels (69% of control), and the remaining vessels had an altered phenotype, being covered with significantly more pericytes (13x control). Final tumor size was significantly less than controls in all tumor models, with combination therapy having a greater antitumor effect than either monotherapy. CONCLUSION: The combination of IFN-beta and rapamycin altered the vasculature of neuroblastoma xenografts and resulted in significant tumor inhibition. The use of combinations of antiangiogenic agents should be further evaluated for the treatment of neuroblastoma and other solid tumors
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Research Department of Haematology
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by